Recent Research Analysts’ Ratings Updates for Eyepoint Pharmaceuticals (EYPT)

Eyepoint Pharmaceuticals (NASDAQ: EYPT) has recently received a number of price target changes and ratings updates:

• 8/22/2026 – Eyepoint Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/18/2026 – Eyepoint Pharmaceuticals had its price target lowered by Citigroup Inc. to $17.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Eyepoint Pharmaceuticals was downgraded by Chardan Capital from “buy” to “neutral”. They now have a $5.00 price target on the stock.
• 8/18/2026 – Eyepoint Pharmaceuticals had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $5.00 price target on the stock.
• 8/18/2026 – Eyepoint Pharmaceuticals had its “neutral” rating reaffirmed by HC Wainwright.
• 8/17/2026 – Eyepoint Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/17/2026 – Eyepoint Pharmaceuticals was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $5.00 price target on the stock.
• 8/17/2026 – Eyepoint Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. to $8.00. They now have a “buy” rating on the stock.
• 8/17/2026 – Eyepoint Pharmaceuticals had its “neutral” rating reaffirmed by JPMorgan Chase & Co..
• 8/17/2026 – Eyepoint Pharmaceuticals was downgraded by Cantor Fitzgerald from “overweight” to “neutral”.
• 8/17/2026 – Eyepoint Pharmaceuticals had its “neutral” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock, down from $65.00.
• 8/7/2026 – Eyepoint Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $65.00 price target on the stock.
• 8/6/2026 – Eyepoint Pharmaceuticals had its price target raised by Cantor Fitzgerald from $47.00 to $55.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Eyepoint Pharmaceuticals had its price target lowered by HC Wainwright from $30.00 to $27.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Eyepoint Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Eyepoint Pharmaceuticals is now covered by Stifel Nicolaus. They set a “buy” rating and a $40.00 price target on the stock.
• 7/8/2026 – Eyepoint Pharmaceuticals is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $47.00 price target on the stock.
• 7/1/2026 – Eyepoint Pharmaceuticals had its price target raised by Chardan Capital from $29.00 to $65.00. They now have a “buy” rating on the stock.

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.